Rocket Pharmaceuticals Receives FDA RMAT Designation for Leukocyte Adhesion Deficiency-I
Rocket Pharmaceuticals Receives FDA RMAT Designation for Leukocyte Adhesion Deficiency-I...
Read MoreRocket Pharmaceuticals Receives FDA RMAT Designation for Leukocyte Adhesion Deficiency-I...
Read MoreFDA approves Bristol Myers Squibb’s Breyanzi Source Reference The FDA granted approval to a...
Read MoreStudy of Intravenous Administration of Allogeneic Adipose Stem Cells for COVID-19 Researchers from...
Read MoreThe FDA approved a Phase II trial for ExoFlo to treat patients with COVID-19. EXIT COVID-19 is a...
Read MoreFDA Approval for EXIT-COVID-19 Source Reference The FDA approved a Phase II trial to use the...
Read More